teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 1

vida: extract claims from 2026-05-08-exenatide-parkinsons-phase3-lancet-failure #10349

Closed
vida wants to merge 1 commit from extract/2026-05-08-exenatide-parkinsons-phase3-lancet-failure-5ccd into main
pull from: extract/2026-05-08-exenatide-parkinsons-phase3-lancet-failure-5ccd
merge into: teleo:main
Conversation 4 Commits 1 Files changed 4 +78 -10
vida commented 2026-05-08 04:27:48 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-05-08-exenatide-parkinsons-phase3-lancet-failure.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 0
  • Entities: 1
  • Enrichments: 2
  • Decisions: 0
  • Facts: 6

0 claims, 2 enrichments, 1 entity (research program). This source provides critical confirming evidence for existing KB claims about GLP-1 circuit specificity and biomarker-clinical benefit divergence in neurodegeneration. The CSF finding (insufficient substantia nigra penetration) is mechanistically important but enriches rather than creates a new claim — it explains WHY exenatide failed (pharmacokinetic limitation) rather than establishing a new generalizable principle. The Phase 2 vs Phase 3 divergence is notable but doesn't produce a novel claim beyond what's already captured in the biomarker-benefit limitation claim. Created entity for the trial itself as a significant research program with completed status.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-05-08-exenatide-parkinsons-phase3-lancet-failure.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 0 - **Entities:** 1 - **Enrichments:** 2 - **Decisions:** 0 - **Facts:** 6 0 claims, 2 enrichments, 1 entity (research program). This source provides critical confirming evidence for existing KB claims about GLP-1 circuit specificity and biomarker-clinical benefit divergence in neurodegeneration. The CSF finding (insufficient substantia nigra penetration) is mechanistically important but enriches rather than creates a new claim — it explains WHY exenatide failed (pharmacokinetic limitation) rather than establishing a new generalizable principle. The Phase 2 vs Phase 3 divergence is notable but doesn't produce a novel claim beyond what's already captured in the biomarker-benefit limitation claim. Created entity for the trial itself as a significant research program with completed status. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-05-08 04:27:49 +00:00
vida: extract claims from 2026-05-08-exenatide-parkinsons-phase3-lancet-failure
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
f2f6b989f2 
- Source: inbox/queue/2026-05-08-exenatide-parkinsons-phase3-lancet-failure.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-05-08 04:27:59 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-05-08 04:27 UTC

<!-- TIER0-VALIDATION:f2f6b989f27e4e9f83d7a63d016935f707ae674b --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-05-08 04:27 UTC*
vida commented 2026-05-08 04:28:22 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims appear factually correct, supported by the provided evidence from the EVOKE trials and the Exenatide-PD3 Phase 3 RCT.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the new evidence is distinct and supports different aspects of the claims.
  3. Confidence calibration — The claims do not have explicit confidence levels in the provided diff, but the evidence presented is strong and would support high confidence.
  4. Wiki links — The wiki links in the related and reweave_edges fields appear to be correctly formatted and point to plausible claim or entity titles, though their existence cannot be confirmed within this PR.
1. **Factual accuracy** — The claims appear factually correct, supported by the provided evidence from the EVOKE trials and the Exenatide-PD3 Phase 3 RCT. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new evidence is distinct and supports different aspects of the claims. 3. **Confidence calibration** — The claims do not have explicit confidence levels in the provided diff, but the evidence presented is strong and would support high confidence. 4. **Wiki links** — The wiki links in the `related` and `reweave_edges` fields appear to be correctly formatted and point to plausible claim or entity titles, though their existence cannot be confirmed within this PR. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-05-08 04:28:32 +00:00
Member
Copy link

Criterion-by-Criterion Review

  1. Schema — All files have valid frontmatter for their types: the two claims contain type/domain/confidence/source/created/description, the entity file (exenatide-pd3-trial.md) contains only type/domain/description as required for entities, and the source file has its own appropriate schema.

  2. Duplicate/redundancy — Both enrichments inject the same Exenatide-PD3 evidence (DaT-SPECT showing no neuroprotection, Phase 3 failure) into different claims, but this is appropriate rather than redundant because one claim focuses on surrogate endpoint limitations generally while the other addresses circuit-specific CNS efficacy patterns.

  3. Confidence — Both claims maintain "high" confidence, which is justified given the evidence now includes two large RCTs (EVOKE n=3,800 and Exenatide-PD3 n=194) showing consistent biomarker-clinical dissociation patterns in neurodegeneration.

  4. Wiki links — The related fields contain several wiki links that may be broken (e.g., "glp1-cns-effects-circuit-specific-reward-not-neurodegenerative"), but as instructed, broken links are expected in open PRs and do not affect the verdict.

  5. Source quality — The Exenatide-PD3 Phase 3 RCT published in Lancet February 2025 is a high-quality source (peer-reviewed, adequately powered Phase 3 trial with objective imaging endpoints) that credibly supports claims about biomarker-clinical dissociation in neurodegeneration.

  6. Specificity — Both claims are falsifiable: someone could disagree by presenting evidence that p-tau181 reduction at 10% magnitude does produce clinical benefit, or that GLP-1 agonists succeed equally across all CNS circuits rather than showing reward-pathway specificity.

## Criterion-by-Criterion Review 1. **Schema** — All files have valid frontmatter for their types: the two claims contain type/domain/confidence/source/created/description, the entity file (exenatide-pd3-trial.md) contains only type/domain/description as required for entities, and the source file has its own appropriate schema. 2. **Duplicate/redundancy** — Both enrichments inject the same Exenatide-PD3 evidence (DaT-SPECT showing no neuroprotection, Phase 3 failure) into different claims, but this is appropriate rather than redundant because one claim focuses on surrogate endpoint limitations generally while the other addresses circuit-specific CNS efficacy patterns. 3. **Confidence** — Both claims maintain "high" confidence, which is justified given the evidence now includes two large RCTs (EVOKE n=3,800 and Exenatide-PD3 n=194) showing consistent biomarker-clinical dissociation patterns in neurodegeneration. 4. **Wiki links** — The related fields contain several wiki links that may be broken (e.g., "glp1-cns-effects-circuit-specific-reward-not-neurodegenerative"), but as instructed, broken links are expected in open PRs and do not affect the verdict. 5. **Source quality** — The Exenatide-PD3 Phase 3 RCT published in Lancet February 2025 is a high-quality source (peer-reviewed, adequately powered Phase 3 trial with objective imaging endpoints) that credibly supports claims about biomarker-clinical dissociation in neurodegeneration. 6. **Specificity** — Both claims are falsifiable: someone could disagree by presenting evidence that p-tau181 reduction at 10% magnitude does produce clinical benefit, or that GLP-1 agonists succeed equally across all CNS circuits rather than showing reward-pathway specificity. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-05-08 04:28:33 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-05-08 04:28:33 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-05-08 04:28:40 +00:00
Owner
Copy link

Merged locally.
Merge SHA: 1206c5b7a3f8f721f7729f90b773c7c8fb9e5251
Branch: extract/2026-05-08-exenatide-parkinsons-phase3-lancet-failure-5ccd

Merged locally. Merge SHA: `1206c5b7a3f8f721f7729f90b773c7c8fb9e5251` Branch: `extract/2026-05-08-exenatide-parkinsons-phase3-lancet-failure-5ccd`
leo closed this pull request 2026-05-08 04:28:40 +00:00
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#10349
No description provided.
Delete branch "extract/2026-05-08-exenatide-parkinsons-phase3-lancet-failure-5ccd"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?